Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 20/20 | 0.55 |
| ▸ | PRKCD | Q05655 | 14/20 | 0.55 |
| ▸ | PRKCA | P17252 | 6/20 | 0.55 |
| ▸ | PRKCG | P05129 | 1/20 | 0.55 |
| ▸ | PRKCB | P05771 | 1/20 | 0.55 |
| ▸ | PRKCH | P24723 | 1/20 | 0.55 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.55 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL800472 | 0.93 | PRKCQ (0.53) | PRKCQPRKCDPRKCAPRKCGPRKCB | |
| SCHEMBL800342 | 0.91 | PRKCQ (0.56) | PRKCQPRKCDPRKCAPRKCGPRKCB | |
| SCHEMBL799915 | 0.90 | PRKCQ (0.53) | PRKCQPRKCDPRKCAPRKCGPRKCB | |
| SCHEMBL800206 | 0.89 | PRKCQ (0.51) | PRKCQPRKCDPRKCAPRKCGPRKCB | |
| SCHEMBL9882205 | 0.85 | PRKCQ (0.52) | PRKCQPRKCDPRKCA | |
| SCHEMBL14725880 | 0.84 | PRKCQ (0.56) | PRKCQPRKCDPRKCAPRKCGPRKCB | |
| SCHEMBL16848401 | 0.84 | PRKCQ (0.78) | PRKCQPRKCDPRKCAPRKCGPRKCB | |
| SCHEMBL800481 | 0.84 | PRKCQ (0.78) | PRKCQPRKCDPRKCAPRKCGPRKCB | |
| SCHEMBL799902 | 0.84 | PRKCQ (0.78) | PRKCQPRKCDPRKCAPRKCGPRKCB | |
| SCHEMBL22412741 | 0.84 | PRKCQ (0.78) | PRKCQPRKCDPRKCAPRKCGPRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067932-B2 | Pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067932-B2 | Pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-06-30 | — | — | US | disclosed |
| US-20120071494-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071494-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071494-A1 | PYRAZOLOPYRIDINE KINASE INHIBITORS | MAP3K5, MAP3K20, MAP3K1 | PRKCQ 41/4885PRKCD 111/4885PRKCA 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.